Immune Activation Anti-Cancer Antiviral Gut Health Metabolic Patents
Home›Topics› Anti-Cancer Research
Research Topic

Anti-Cancer Research

Peer-reviewed evidence on Aureobasidium pullulans beta glucan’s anti-tumor mechanisms: NK cell activation, PD-L1 synergy, TSP-1 upregulation, and a Phase I-II clinical trial.

30+ Studies Phase I-II Clinical Trial PD-L1 Synergy (2022) TSP-1 Upregulation
Research findings only. Not a claim of cancer treatment or cure. Consult a qualified oncologist for medical decisions.
Direct Answer

Preclinical studies document anti-tumor effects via NK cell activation (CR3 receptor), dendritic cell stimulation, PD-L1 checkpoint inhibitor synergy (2022), and TSP-1 upregulation (anti-angiogenic mechanism). A Phase I-II clinical trial evaluated oral beta glucan as adjunct therapy in patients with advanced malignancies receiving chemotherapy — reporting safety and preliminary NK activity biomarker data. No cancer treatment claims can be made from current evidence.

Mechanisms

Anti-Tumor Mechanisms Documented in Research

Four distinct pathways have been studied in peer-reviewed literature connecting Aureobasidium beta glucan to anti-tumor immune activity.

NK Cell Cytotoxicity via CR3

Beta glucan binds CR3 (CD11b) on NK cells, priming enhanced cytotoxic activity against tumor cells. Tumor killing is mediated via perforin and granzyme release. CR3-primed NK cells show significantly increased killing rates in in vitro cancer cell assays.

Dendritic Cell — T Cell Priming

Dendritic cells activated by beta glucan via Dectin-1 produce IL-12, driving Th1 T cell differentiation. CD8+ cytotoxic T cells primed this way target tumor-specific antigens — a mechanism studied in anti-tumor vaccine adjuvancy models.

PD-L1 Checkpoint Synergy (2022)

A 2022 publication demonstrated synergy between Aureobasidium beta glucan and PD-L1 checkpoint inhibitor therapy in a mouse tumor model. Combined treatment produced greater tumor growth inhibition than either agent alone — suggesting beta glucan as a potential checkpoint therapy adjunct.

TSP-1 Anti-Angiogenic Effect

Thrombospondin-1 (TSP-1), an endogenous anti-angiogenic and tumor-suppressive glycoprotein, is upregulated following beta glucan treatment in some studies. TSP-1 inhibits tumor neovascularization — limiting tumor growth and metastatic potential.

Key Studies

Landmark Anti-Cancer Research

Selected peer-reviewed studies on Aureobasidium pullulans beta glucan and cancer.

Clinical Trial
Clinical Trial: Beta Glucan as Adjunct to Chemotherapy in Advanced Malignancies
Evaluated safety and NK cell activity biomarkers in cancer patients receiving standard chemotherapy. Documented tolerability and significant NK activity maintenance vs. chemotherapy-alone controls.
Peer-reviewed journal · DOI-verified · PMID indexed
In Vivo
In Vivo (2022): Beta Glucan and PD-L1 Checkpoint Inhibitor Synergy in Mouse Model
Combined beta glucan + anti-PD-L1 antibody produced significantly greater tumor growth inhibition than either agent alone in mouse model. NK and CD8+ T cell infiltration increased in combination group vs. monotherapy.
Cancer Immunology Research · Indexed in Research Archive
In Vitro
In Vitro: TSP-1 Upregulation and Anti-Angiogenic Mechanism
Beta glucan treatment upregulated TSP-1 (thrombospondin-1) expression in endothelial cells, significantly reducing VEGF-stimulated tube formation in vitro. Proposed as a complementary anti-angiogenic mechanism alongside NK activation.
Carbohydrate Polymers · Indexed in Research Archive
In Vivo
In Vivo: NK Cell-Mediated Tumor Suppression in Sarcoma Mouse Model
Oral administration of Aureobasidium beta glucan significantly reduced tumor volume in mice inoculated with sarcoma cells. Depletion of NK cells abolished the effect, confirming NK-dependent mechanism.
International Journal of Cancer Research · DOI-verified
View All Anti-Cancer Studies
Common Questions

Anti-Cancer FAQ

Preclinical studies show anti-tumor effects via NK cell activation, dendritic cell stimulation, PD-L1 synergy, and TSP-1 upregulation. A Phase I-II clinical trial evaluated it in advanced cancer patients. No cancer treatment claims can be made — consult an oncologist.
A 2022 publication found that combining Aureobasidium beta glucan with a PD-L1 checkpoint inhibitor produced greater tumor growth inhibition than either agent alone in a mouse model. This suggests potential as an immunotherapy adjunct — not a standalone treatment.
Thrombospondin-1 (TSP-1) is an endogenous glycoprotein that inhibits angiogenesis (new blood vessel formation in tumors). Tumors require blood vessel growth to grow and metastasize. TSP-1 upregulation by beta glucan may limit tumor vascularization as a complementary anti-tumor mechanism.
The trial evaluated oral Aureobasidium beta glucan in patients with advanced solid tumors receiving chemotherapy. It documented safety (no significant adverse events) and measured NK cell activity as a biomarker — showing that NK activity was maintained in the beta glucan group versus decline in chemotherapy-alone controls.
This page presents research findings only. Aureobasidium beta glucan is not approved as a cancer treatment. All medical decisions should be made in consultation with a qualified oncologist.

Browse All Anti-Cancer Studies

30+ indexed studies with abstracts, AI summaries, DOI links, and PMID references.

Open Research Archive